Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-8055. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 20/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 1/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | RICTOR | Q6R327 | 1/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 1/20 | 1.00 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-8055 SCHEMBL2929203 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL7861478 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL29396804 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL29388315 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL1219191 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL19263472 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL24264610 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL7861464 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL4409051 | 0.96 | MTOR (0.92) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL4408875 | 0.96 | MTOR (0.92) | MTORFECHPIK3R1PIK3CAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3596 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| WO-2026099917-A1 | METHOD FOR PRODUCING USEFUL SUBSTANCE, CULTURE SOLUTION FOR CULTURING ALGAE, AND DEVICE FOR PRODUCING USEFUL SUBSTANCE | ＮＴＴ株式会社 | 2026-05-15 | — | — | WO | claimed |
| CN-122028938-A | Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor | 德彪药业国际股份公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260124274-A1 | METHODS OF INCREASING READTHROUGH OF A PREMATURE TERMINATION CODON | UNIV RAMOT (IL) | 2026-05-07 | — | — | US | claimed |
| EP-4729121-A2 | NOVEL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DERMAL DISORDERS | Drexel University (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-12576069-B2 | Compositions and methods for treating slow-flow vascular malformations | YALE UNIVERSITY (US) | 2026-03-17 | — | — | US | claimed |
| EP-3947736-B1 | PROGNOSIS METHOD OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2026-03-11 | — | — | EP | claimed |
| EP-2427174-A1 | MTOR PATHWAY INHIBITORS FOR TREATING OCULAR DISORDERS | Santen Pharmaceutical Co., Ltd (JP) | 2012-03-14 | — | — | EP | claimed |
| JP-2011512395-A | — | — | 2011-04-21 | — | — | JP | claimed |
| US-20110028471-A1 | COMBINATION THERAPY 238 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | US | claimed |
| EP-2262504-A1 | COMBINATION THERAPY 238 | AstraZeneca AB (SE) | 2010-12-22 | — | — | EP | claimed |
| WO-2010129622-A1 | MTOR PATHWAY INHIBITORS FOR TREATING OCULAR DISORDERS | MACUSIGHT, INC. (US) | 2010-11-11 | — | — | WO | claimed |
| EP-2217234-A2 | COMBINATIONS OF MEK INHIBITORS WITH MTOR INHIBITORS | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | claimed |
| US-20090318434-A1 | COMPOSITION AND PROCESS - 356 | ASTRAZENECA AB (SE) | 2009-12-24 | — | — | US | claimed |
| WO-2009104019-A1 | COMBINATION THERAPY 238 | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | WO | claimed |
| WO-2009050506-A2 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | claimed |
| US-20090099174-A1 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | claimed |